Skip to main content
Helix BioPharma Corp. logo

Helix BioPharma Corp. — Investor Relations & Filings

Ticker · HBP ISIN · CA4229102088 LEI · 9845005F4A1779D70B60 TSX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country CA Canada
Listing TSX HBP

About Helix BioPharma Corp.

https://www.helixbiopharma.com/

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company specializing in immune-oncology. The company is dedicated to developing innovative cancer treatments, focusing on hard-to-treat solid tumors. Helix employs a proprietary platform technology centered on bio-conjugates, which are designed to deliver precision targeting against malignant cells. This approach aims to create novel therapies that render challenging cancers vincible. The company's pipeline includes the clinical advancement of its lead candidate, L-DOS47.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Transaction in Own Shares Classification · 85% confidence The document is a corporate press release announcing the board’s grant of 1,297,000 incentive stock options and the cancellation of 2,200,000 previously granted options under the company’s equity compensation plan. This is an announcement of share‐based issuance/cancellation rather than a financial report, management change, dividend notice, or AGM material. Under the filing definitions, it falls under “Transaction in Own Shares (POS)” which covers share repurchase/issuance activities.
2026-05-22 English
News release - English.pdf
Share Issue/Capital Change Classification · 80% confidence The document is a news release announcing the board’s grant of 1,297,000 new incentive stock options and the cancellation of 2,200,000 previously granted options under the Company’s equity compensation plan. This constitutes a change in the Company’s capital structure (i.e., potential share issuance via option grants and cancellation of outstanding options). It is not a full financial report, regulatory certification, or personal insider trade report. It fits the definition of a Share Issue/Capital Change announcement (SHA).
2026-05-22 English
News release - English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a corporate news release announcing the grant of new incentive stock options and cancellation of previously granted options under the company’s equity compensation plan. It does not contain financial statements or voting results, nor is it a regulatory filing of a report. This is an announcement of a capital change event (issuance and cancellation of option rights), which falls under the Share Issue/Capital Change category.
2026-05-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Helix BioPharma Corp. announcing the extension of a research and exclusive option agreement with metaShape Pharma. It details the nature of the agreement, the strategic rationale, and provides background information on both companies. It does not fit into specific categories like financial reports, board changes, or shareholder voting results. As it is a general corporate announcement regarding a business agreement, it falls under the 'Regulatory Filings' (RNS) category, which serves as the fallback for general corporate news and announcements.
2026-02-05 English
News release - English.pdf
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 5,000 characters) that announces the filing and availability of the company's interim financial statements and MD&A on SEDAR+. It does not contain the financial statements themselves, but rather serves as a notification of their publication. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-12-16 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 40% confidence The document is Form 52-109F1, the CEO’s “Certification of Annual Filings” under Canada’s National Instrument 52-109 attached to the annual filing. It is not the full annual report (10-K) or MD&A itself, nor an earnings release or AGM material, but a regulatory certificate filed with securities regulators. It does not announce the availability of any report, so it best fits the fallback “Regulatory Filings” category (RNS).
2025-10-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.